{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:27:59Z","timestamp":1792682879531,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Elranatamab, a BCMA-CD3 bispecific antibody, has demonstrated robust activity in relapsed\/refractory multiple myeloma (RRMM), but real-world outcomes remain poorly defined. We conducted a multicenter retrospective study of 130 patients treated with commercial elranatamab across nine U.S. academic centers. The cohort was heavily pretreated (91% triple-class refractory, 49% penta-refractory), with 49% previously exposed to BCMA-targeted therapies. Only 22% would have met eligibility for MagnetisMM-3 cohort A. The overall response rate (ORR) was 65%, including \u2265CR in 36%. Median progression-free survival (PFS) and overall survival (OS) were 4.3 and 14.6 months, respectively, shorter than MagnetisMM-3. Elevated LDH and low hemoglobin independently predicted poor outcomes and were incorporated into the novel ALPS (Anemia-LDH Prognostic System) score, which stratified patients into distinct risk groups for ORR, OS, PFS, and duration of response. Prior BCMA exposure reduced depth of response, with inferior OS observed in those treated within one year of prior therapy. Infections occurred in 38% of patients. Intravenous immunoglobulin supplementation, modeled as a time-dependent covariate, was associated with improved infection-free survival and PFS. While the incidence of CRS was modestly lower than in MagnetisMM-3, ICANS occurred more frequently in this real-world cohort. These findings highlight the efficacy, limitations, and supportive care needs of elranatamab in a frailer, more heterogeneous real-world RRMM population.<\/jats:p>","DOI":"10.1038\/s41408-026-01477-z","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:32:49Z","timestamp":1774589569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-4578","authenticated-orcid":false,"given":"Andrew J.","family":"Portuguese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2739-2265","authenticated-orcid":false,"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-5870","authenticated-orcid":false,"given":"Omar","family":"Castaneda Puglianini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6618-440X","authenticated-orcid":false,"given":"Corbin","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0639-3768","authenticated-orcid":false,"given":"Brandon J.","family":"Blue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid C.","family":"Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H.","family":"Shain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-0325","authenticated-orcid":false,"given":"Utkarsh","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6528","authenticated-orcid":false,"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":false,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3778-5499","authenticated-orcid":false,"given":"Hossam M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9193-0059","authenticated-orcid":false,"given":"Oren","family":"Pasvolsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3928-6590","authenticated-orcid":false,"given":"Mahmoud","family":"Gaballa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9711-7473","authenticated-orcid":false,"given":"Hector","family":"Garcia-Pleitez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2806-2583","authenticated-orcid":false,"given":"Damian","family":"Mikulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3678-2805","authenticated-orcid":false,"given":"Lindsay","family":"Fogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Zolotov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Sannareddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-8557","authenticated-orcid":false,"given":"Aimaz","family":"Afrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2111-2461","authenticated-orcid":false,"given":"Kelley","family":"Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3587-7975","authenticated-orcid":false,"given":"Danai","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Cassano Cassano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5768-9396","authenticated-orcid":false,"given":"Megan M.","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-2703","authenticated-orcid":false,"given":"Hamza","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeries","family":"Kort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4948-5507","authenticated-orcid":false,"given":"Shonali","family":"Midha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-4277","authenticated-orcid":false,"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-2698","authenticated-orcid":false,"given":"Douglas","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0693-4202","authenticated-orcid":false,"given":"Noa","family":"Biran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Grajales-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"1477_CR1","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 magnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"},{"key":"1477_CR2","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1182\/blood-2024-208192","volume":"144","author":"HM Prince","year":"2024","unstructured":"Prince HM, Bahlis NJ, Rodr\u00edguez-Otero P, Karlin L, Akard L, Varshavsky-Yanovsky A, et al. MagnetisMM-3: long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma. Blood. 2024;144:4738.","journal-title":"Blood"},{"key":"1477_CR3","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1002\/hem3.136","volume":"8","author":"MH Tomasson","year":"2024","unstructured":"Tomasson MH, Iida S, Niesvizky R, Mohty M, Bahlis NJ, Martinez-Lopez J, et al. Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study. Hemasphere. 2024;8:e136.","journal-title":"Hemasphere"},{"key":"1477_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","volume":"4","author":"G Lancman","year":"2023","unstructured":"Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, et al. IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-bcma bispecific antibodies. Blood Cancer Discov. 2023;4:440\u201351.","journal-title":"Blood Cancer Discov"},{"key":"1477_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01282-0","volume":"15","author":"M Mohan","year":"2025","unstructured":"Mohan M, Szabo A, Cheruvalath H, Clennon A, Bhatlapenumarthi V, Patwari A, et al. Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma. Blood Cancer J. 2025;15:74.","journal-title":"Blood Cancer J"},{"key":"1477_CR6","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e46.","journal-title":"Lancet Oncol"},{"key":"1477_CR7","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1182\/blood-2015-05-647636","volume":"126","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar SV, Richardson P, San Miguel JF. Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood. 2015;126:921\u20132.","journal-title":"Blood"},{"key":"1477_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1477_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J Hematol Oncol. 2023;16:88.","journal-title":"J Hematol Oncol"},{"key":"1477_CR10","unstructured":"R Core Team. R: A language and environment for statistical computing. Version 4.4.3 (2025-02-28) ed. Vienna, Austria: R Foundation for Statistical Computing; 2025."},{"key":"1477_CR11","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1080\/02664763.2018.1558187","volume":"46","author":"AR Smith","year":"2019","unstructured":"Smith AR, Goodrich NP, Beil CA, Liu Q, Merion RM, Gillespie BW, et al. Graphical representation of survival curves in the presence of time-dependent categorical covariates with application to liver transplantation. J Appl Stat. 2019;46:1702\u201313.","journal-title":"J Appl Stat"},{"key":"1477_CR12","first-page":"S23","volume":"31","author":"Y Li","year":"2025","unstructured":"Li Y, Qiao Y, Gao F, Gauthier J, Zhang QE, Voutsinas JM, et al. A novel R shiny tool TVCurveTM for survival analysis with time-varying covariate in oncology clinical studies: overcoming biases and enhancing collaboration. Transplant Cell Ther, Off Publ Am Soc Transplant Cell Ther. 2025;31:S23\u2013S4.","journal-title":"Transplant Cell Ther, Off Publ Am Soc Transplant Cell Ther"},{"key":"1477_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41409-019-0679-x","volume":"55","author":"J Gauthier","year":"2020","unstructured":"Gauthier J, Wu QV, Gooley TA. Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians. Bone Marrow Transpl. 2020;55:675\u201380.","journal-title":"Bone Marrow Transpl"},{"key":"1477_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01200-w","volume":"14","author":"F Malard","year":"2024","unstructured":"Malard F, Bobin A, Labopin M, Karlin L, Frenzel L, Roussel M, et al. Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM. Blood Cancer J. 2024;14:219.","journal-title":"Blood Cancer J"},{"key":"1477_CR15","unstructured":"Anticytokine therapy and corticosteroids for cytokine release syndrome and for neurotoxicity following T-cell engager or CAR T-cell therapy: rapid review. CADTH Health Technology Review. Ottawa (ON) 2024."},{"key":"1477_CR16","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1002\/cncr.35316","volume":"130","author":"X Wang","year":"2024","unstructured":"Wang X, Zhang B, Zhang Q, Zhou H, Sun Q, Zhou Y, et al. Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia. Cancer. 2024;130:2660\u20139.","journal-title":"Cancer"},{"key":"1477_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00963-y","volume":"13","author":"SA Scott","year":"2023","unstructured":"Scott SA, Marin EM, Maples KT, Joseph NS, Hofmeister CC, Gupta VA, et al. Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience. Blood Cancer J. 2023;13:191.","journal-title":"Blood Cancer J"},{"key":"1477_CR18","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.1182\/bloodadvances.2025016911","volume":"9","author":"A Kowalski","year":"2025","unstructured":"Kowalski A, Lykon J, Diamond B, Coffey D, Kaddoura M, Maura F, et al. Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies. Blood Adv. 2025;9:4979\u201386.","journal-title":"Blood Adv"},{"key":"1477_CR19","first-page":"1065","volume":"30","author":"FL Locke","year":"2024","unstructured":"Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Jacobson CA, Braunschweig I, et al. Tocilizumab prophylaxis following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Transpl Cell Ther. 2024;30:1065\u201379.","journal-title":"Transpl Cell Ther"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01477-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01477-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01477-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:18:04Z","timestamp":1774984684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01477-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1477"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01477-z","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AJP reports consulting for Capvision and Karyopharm. SR reports research funding from Janssen Research Developments and Nexcella, and participation on advisory panels for Janssen, Nexcella, Prothena Biosciences, Pfizer, and Kite Pharma. RB reports consulting for AbbVie, Adaptive Biotechnologies, Bristol Myers Squibb, Caribou Biosciences, Genentech, Gilead\/Kite, GSK, Janssen, Karyopharm, Legend Biotech, Poseida Therapeutics, Pfizer, Sanofi, and SparkCures, and research funding from AbbVie, Bristol Myers Squibb, Janssen, Novartis, Pack Health, Prothena, and Sanofi. FA has served as an advisor or speaker for Bristol Myers Squibb, Celgene, Caribou Biosciences, GI Innovation, and Poseida Therapeutics, and has received research funding from Allogene Therapeutics, Celgene, Bristol Myers Squibb, and Caribou Biosciences. FL has served as a consultant or advisor to A2, Adaptive Biotechnologies, Adaptimmune, Allogene, Amgen, AstraZeneca, Bluebird Bio, Bristol Myers Squibb, Calibr, Caribou, EcoR1, GLG, Iovance, Kite, Janssen, Legend Biotech, Miltenyi, Novartis, Sana, Pfizer, and Poseida; serves on the NCI CAR T-cell Therapy Safety Oversight DSMB; has received institutional research funding from 2SeventyBio, Allogene, Bristol Myers Squibb, Incyte, Kite, the Leukemia & Lymphoma Society, the Mark Foundation, and the National Cancer Institute; holds institutional patents in cellular immunotherapy; and has participated in educational activities with Aptitude Health, ASH, ASTCT, Clinical Care Options, and the Society for Immunotherapy of Cancer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}